Cartalax + BPC-157 + TB-500 + KPV

Molecular Profile

Type

Peptide blend

Components

Mechanism & Target Class

This blend combines four structurally and mechanistically distinct molecules. Cartalax (Ala-Glu-Asp; AED) belongs to the class of ultrashort peptide bioregulators studied for proposed nuclear-entry and interaction with histone proteins and DNA promoter sequences, with downstream changes in structural matrix protein transcription examined in cell-culture models. BPC-157 is a 15-residue synthetic peptide whose primary literature maps to the nitric oxide (NO) system and VEGFR2-associated pathways — specifically the VEGFR2–Akt–eNOS and Src–Caveolin-1–eNOS axes — as well as growth-hormone-receptor-linked transcriptional readouts in fibroblast models. TB-500, characterized in the indexed literature as an N-terminally acetylated heptapeptide (Ac-LKKTETQ) corresponding to an actin-binding region within a larger endogenous peptide, is studied in the context of G-actin sequestration and cytoskeletal dynamics; this short sequence and the full-length precursor are not established as equivalent and findings from each are attributed separately. KPV (Lys-Pro-Val) is studied primarily through PepT1 (SLC15A1)-mediated intestinal uptake and downstream NF-κB and MAPK pathway engagement in epithelial and immune cell models. The blend has no single shared molecular target; each component is associated with distinct receptor contexts and signaling programs.

Storage & Handling

Lyophilized

-20°C for long-term preservation; protect from light and moisture.

Handling

Multi-peptide formulation; individual component stabilities vary; avoid excessive physical agitation post-reconstitution.

Primary Database

PubChem CID 9941957 (BPC-157 component) ↗

References (17)

1. Reviews

   1

   Sikiric P, et al. (2016). Curr Neuropharmacol

   DOI: 10.2174/1570159x13666160502153022PubMed 27138887

2. 2

   Goldstein AL, Hannappel E, Kleinman HK. (2005). Trends Mol Med

   DOI: 10.1016/j.molmed.2005.07.004PubMed 16109503

3. 3

   Vasireddi N, et al. (2025). HSS J

   DOI: 10.1177/15563316251355551PubMed 40756949

4. 4

   McGuire FP, et al. (2025). Curr Rev Musculoskelet Med

   DOI: 10.1007/s12178-025-09990-7PubMed 40789979

5. 5

   Khavinson VKh, et al. (2021). Molecules

   DOI: 10.3390/molecules26227053PubMed 34834147

6. Primary research

   6

   Chang CH, et al. (2011). J Appl Physiol (1985)

   DOI: 10.1152/japplphysiol.00945.2010PubMed 21030672

7. 7

   Dalmasso G, et al. (2008). Gastroenterology

   DOI: 10.1053/j.gastro.2007.10.026PubMed 18061177

8. 8

   Khavinson VKh, et al. (2001). Bull Exp Biol Med

   DOI: 10.1023/a:1012595029177PubMed 11550020

9. 9

   Hsieh MJ, et al. (2020). Sci Rep

   DOI: 10.1038/s41598-020-74022-yPubMed 33051481

10. 10

    Hsieh MJ, et al. (2017). J Mol Med (Berl)

    DOI: 10.1007/s00109-016-1488-yPubMed 27847966

11. 11

    Chang CH, et al. (2014). Molecules

    DOI: 10.3390/molecules191119066PubMed 25415472

12. 12

    Xiao B, et al. (2017). Mol Ther

    DOI: 10.1016/j.ymthe.2016.11.020PubMed 28143741

13. 13

    Viennois E, et al. (2016). Cell Mol Gastroenterol Hepatol

    DOI: 10.1016/j.jcmgh.2016.01.006PubMed 27458604

14. 14

    Kannengiesser K, et al. (2008). Inflamm Bowel Dis

    DOI: 10.1002/ibd.20334PubMed 18092346

15. 15

    Sun J, et al. (2021). ACS Biomater Sci Eng

    DOI: 10.1021/acsbiomaterials.1c00792PubMed 34547895

16. 16

    Ho EN, et al. (2012). J Chromatogr A

    DOI: 10.1016/j.chroma.2012.09.043PubMed 23084823

17. 17

    Khavinson VKh, et al. (2016). Bull Exp Biol Med

    DOI: 10.1007/s10517-016-3596-7PubMed 27909961